Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

NCT05981014 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

PROCEDURE: Sentinel Lymph Node Biopsy (SLNB)
DRUG: Doxorubicin
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)
BIOLOGICAL: Interleukin-2
DRUG: Nab-paclitaxel

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University